spacer
home > epc > winter 2002 > paediatric clinical trials - implications for contractors
PUBLICATIONS
European Pharmaceutical Contractor

Paediatric Clinical Trials - Implications for Contractors

The Growth of Paediatric Clinical Trials

Parallel initiatives introduced in the US in the late 1990s have led to unprecedented growth in the field of paediatric clinical trials and the globalisation of activities in this area (see Figure 1). In brief, the Paediatric Rule of 1998 (1) mandates sponsors to collect data from children for labelling purposes. The paediatric provisions of the FDA's Modernisation Act of 1997 (2), recently incorporated into the US Best Pharmaceuticals for Children Act 2002 (3), provides sponsors with an incentive to conduct the trials - an additional six months of patent life for the drug under study. This carrot and stick approach has had a twofold effect. Firstly, the sheer number of trials has increased enormously. Recent FDA data shows that since the incentives came into effect, the FDA has requested nearly 600 trials involving around 35,000 children.

Secondly, paediatric trials are now being seen at a much earlier stage of the drug development process. Indeed, the recent ICH document E-11 (4) recommends the early and urgent initiation of trials for compounds that will treat serious childhood diseases, or those that may be thought of as a considerable therapeutic advance. Traditionally, such trials - if conducted at all - were not usually seen until the drug's adult programme had reached Phase IV, or at least until a significant amount of adult data had been gathered.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

Banner of CRS on Samedan
spacer
By Simon Robinson, Programme Director, International Paediatrics at Intercern

Simon Robinson joined Intercern in 1999. His career in paediatrics and NHS research spans over 10 years, including five years at Great Ormond Street Hospital. In his current role, Simon has established a paediatric clinical research network, which is now rapidly expanding across Europe.

He also leads Intercern's Paediatric Research consultancy service, which helps sponsors to develop acceptable child friendly protocols that are also able to satisfy regulatory demands. He has experience in the majority of paediatric sub-therapy areas. His academic output includes recent articles on paediatrics for Pharmaceutical Physician, GCP Journal, CR Focus, and Paediatric Drugs.


spacer
Simon Robinson
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

World Vaccine Congress

10-12 April 2012, Gaylord National Hotel and Convention Center, Washington, US

The 12th annual World Vaccine Congress Washington brings new scientific and business critical debate, discussion and solutions from the true global pioneers shaping vaccine R&D.
More info >>

 
News and Press Releases

Delta Industrial Services to display at Pharmapack

Delta Industrial Services, a leader in web converting and packaging innovation, will be showcasing some of their recent developments in pharmaceutical manufacturing and pouching.
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.